Company has a lot of potential with their pipeline
Teens coming on results any day
someone wants shares before data is out! Getting close to major move up!
something is brewing
Listen to investor conference in December to researchers and you realize they are amazed at the results they are seeing with their drug pipeline in the field of cancer.
With a full pipeline of drugs that are showing great results in blood cancers, this stock is highly likely to get bought out by Celgene, Novartis or J&J. When results of phase 2 for one of their compounds comes out any day this will fly to teens as institutional investors move in big into this recently IPO'd company.